Trevi Therapeutics to Host Q3 Results Call
The clinical-stage biopharmaceutical company will discuss its quarter ended September 30, 2026, via webcast on November 9.
Updated on Nov. 2, 2026 in Asthma
Trevi Therapeutics will host a conference call and webcast on November 9, 2026, at 4:30 p.m. ET to review financial results for the quarter ended September 30, 2026. The company is developing the investigational therapy Haduvio (oral nalbuphine ER) for chronic cough.
Why it matters
Haduvio is being developed for chronic cough in idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough, conditions for which no FDA-approved therapies currently exist. The call offers an update on the company's progress toward addressing those unmet needs.
Approximately 140,000 U.S. patients have IPF and roughly 228,000 have non-IPF ILD, with 50-60% of the latter experiencing uncontrolled chronic cough. Haduvio showed a statistically significant reduction in cough frequency in clinical trials, but the company's forthcoming results will not be available until the call.
The players
Trevi Therapeutics
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing treatments for chronic cough and related conditions.
The details
Registration for the live conference call and webcast is available through the Investors & News section of the company's website, and phone participants will receive call-in details by email after registering. An archived replay will be available on the company website for 30 days following the event.
Timeline
September 30, 2026: End of the quarter being reported.
November 9, 2026: Conference call and webcast begin at 4:30 p.m. ET.
30 days after the event: Archived webcast replay expires from the company website.
Health Landscape
Chronic cough in idiopathic pulmonary fibrosis and non-IPF interstitial lung disease currently lacks any FDA-approved treatment, leaving a gap that Haduvio is being developed to fill. The company's updates feed into a broader effort to address chronic refractory cough, which affects an estimated 2 to 3 million U.S. patients.
Patients with chronic cough linked to IPF or non-IPF interstitial lung disease currently have no FDA-approved treatment options. Updates from Trevi's call may signal progress toward a potential therapy that could eventually change daily symptom management.
The takeaway
Readers following chronic cough research can watch for Trevi's update on Haduvio, the company's investigational therapy for conditions lacking approved treatments. The archived webcast will remain accessible for 30 days after the event.
What happens next
Trevi Therapeutics will host its conference call and webcast on November 9, 2026, at 4:30 p.m. ET to review its quarter ended September 30, 2026.
Further reading
For broader context on respiratory conditions, explore the Asthma section of our health coverage.
More information
Register for the call and find event details on the Trevi investor event registration page.
Source note: This article includes information reported by The Manila times.
